ANDOVER,
Mass., June 21, 2024 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, today announced
that on June 18, 2024, TransMedics
granted non-qualified stock options to purchase an aggregate of
1,002 shares of its common stock and an aggregate of 657 restricted
stock units to 1 employee, each as a material inducement for the
employee's entry into employment with TransMedics. The grants were
approved by the Compensation Committee of the TransMedics Board of
Directors and were granted in accordance with Nasdaq Listing Rule
5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement
Plan.
TransMedics granted non-qualified stock options to purchase
1,002 shares of TransMedics' common stock and 657 restricted stock
units in the aggregate. The stock options were granted with a per
share exercise price of $145.96, the
closing price of the common stock on the Nasdaq Global Market on
June 18, 2024. Twenty-five percent of
the shares subject to each option will vest on the first yearly
anniversary of the date of the employee's start of employment, with
the remainder vesting in equal monthly installments over the
subsequent three year period, subject to the employee's continued
service with the Company through the applicable vesting date. The
options have a 10-year term and are subject to the terms of the
TransMedics Group, Inc. Inducement Plan. Twenty-five percent of
each restricted stock unit award will vest on the first four
anniversaries of the date of the employee's start of employment,
subject to the employee's continued service with the Company
through the applicable vesting date. The restricted stock units are
subject to the terms of the TransMedics Group, Inc. Inducement
Plan.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian
Johnston
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302179104.html
SOURCE TransMedics Group, Inc.